This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Chemed's (CHE) VITAS Business Strong Amid Coronavirus Crisis
by Zacks Equity Research
Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.
National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat
by Zacks Equity Research
Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.
AMN Healthcare (AMN) Loses 3.3% Despite Q2 Earnings Beat
by Zacks Equity Research
AMN Healthcare (AMN) gained from two of its three core operating segments in Q2.
Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.
PRA Health (PRAH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.
Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up
by Zacks Equity Research
Insulet's (PODD) total Omnipod product line comes up with record revenue growth.
Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.
Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.
Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.
TMO vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. EW: Which Stock Is the Better Value Option?
Cardiovascular Systems (CSII) Misses Q4 Earnings Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.
NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.
ResMed (RMD) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
ResMed's (RMD) top line reflects strong segmental and geographic performance boosted by pandemic-led demand growth for ventilators.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.
LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.
Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q3
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.
DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.
CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.